Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study

Xenofon Baraliakos, Juergen Braun, Atul Deodhar, Denis Poddubnyy, Alan Kivitz, Hasan Tahir, Filip Van Den Bosch, Evie Maria Delicha, Zsolt Talloczy, Anke Fierlinger

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Fingerprint Dive into the research topics of 'Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study'. Together they form a unique fingerprint.

Medicine & Life Sciences